These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. [Influence of levodopa, stalevo on dyskinesia in Parkinson's disease: STRIDE-PD study]. Liashchenko EA; Skripkina NA; Levin OS Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(7 Pt 2):62-8. PubMed ID: 23994933 [TBL] [Abstract][Full Text] [Related]
25. Metabotropic glutamate receptors in Parkinson's disease. Kwan C; Kang W; Kim E; Belliveau S; Frouni I; Huot P Int Rev Neurobiol; 2023; 168():1-31. PubMed ID: 36868628 [TBL] [Abstract][Full Text] [Related]
26. A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson's disease. Le Poul E; Boléa C; Girard F; Poli S; Charvin D; Campo B; Bortoli J; Bessif A; Luo B; Koser AJ; Hodge LM; Smith KM; DiLella AG; Liverton N; Hess F; Browne SE; Reynolds IJ J Pharmacol Exp Ther; 2012 Oct; 343(1):167-77. PubMed ID: 22787118 [TBL] [Abstract][Full Text] [Related]
27. Co-operative binding assay for the characterization of mGlu4 allosteric modulators. Poutiainen P; Kil KE; Zhang Z; Kuruppu D; Tannous B; Brownell AL Neuropharmacology; 2015 Oct; 97():142-8. PubMed ID: 26025660 [TBL] [Abstract][Full Text] [Related]
28. New treatments for the motor symptoms of Parkinson's disease. Vijverman AC; Fox SH Expert Rev Clin Pharmacol; 2014 Nov; 7(6):761-77. PubMed ID: 25318835 [TBL] [Abstract][Full Text] [Related]
29. Discovery of 3-aminopicolinamides as metabotropic glutamate receptor subtype 4 (mGlu4) positive allosteric modulator warheads engendering CNS exposure and in vivo efficacy. Gogliotti RD; Engers DW; Garcia-Barrantes PM; Panarese JD; Gentry PR; Blobaum AL; Morrison RD; Daniels JS; Thompson AD; Jones CK; Conn PJ; Niswender CM; Lindsley CW; Hopkins CR Bioorg Med Chem Lett; 2016 Jun; 26(12):2915-2919. PubMed ID: 27131990 [TBL] [Abstract][Full Text] [Related]
30. Characterization of [ Takano A; Nag S; Jia Z; Jahan M; Forsberg A; Arakawa R; Grybäck P; Duvey G; Halldin C; Charvin D Mol Imaging Biol; 2019 Jun; 21(3):500-508. PubMed ID: 30066121 [TBL] [Abstract][Full Text] [Related]
31. Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease. Duty S Br J Pharmacol; 2010 Sep; 161(2):271-87. PubMed ID: 20735415 [TBL] [Abstract][Full Text] [Related]
32. Discovery, Structure-Activity Relationship, and Antiparkinsonian Effect of a Potent and Brain-Penetrant Chemical Series of Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4. Charvin D; Pomel V; Ortiz M; Frauli M; Scheffler S; Steinberg E; Baron L; Deshons L; Rudigier R; Thiarc D; Morice C; Manteau B; Mayer S; Graham D; Giethlen B; Brugger N; Hédou G; Conquet F; Schann S J Med Chem; 2017 Oct; 60(20):8515-8537. PubMed ID: 28902994 [TBL] [Abstract][Full Text] [Related]
33. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis. Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614 [TBL] [Abstract][Full Text] [Related]
34. Does levodopa slow or hasten the rate of progression of Parkinson's disease? Fahn S; J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436 [TBL] [Abstract][Full Text] [Related]
35. Pharmacological and molecular characterization of the positive allosteric modulators of metabotropic glutamate receptor 2. Lundström L; Bissantz C; Beck J; Dellenbach M; Woltering TJ; Wichmann J; Gatti S Neuropharmacology; 2016 Dec; 111():253-265. PubMed ID: 27590915 [TBL] [Abstract][Full Text] [Related]
36. [Drug therapy in Parkinson's disease]. van Hilten JJ; Roos RA Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151 [TBL] [Abstract][Full Text] [Related]
38. (6aR)-11-amino-N-propyl-noraporphine, a new dopamine D2 and serotonin 5-HT1A dual agonist, elicits potent antiparkinsonian action and attenuates levodopa-induced dyskinesia in a 6-OHDA-lesioned rat model of Parkinson's disease. Zhao R; Lu W; Fang X; Guo L; Yang Z; Ye N; Zhao J; Liu Z; Jia J; Zheng L; Zhao B; Zhang A; Zhen X Pharmacol Biochem Behav; 2014 Sep; 124():204-10. PubMed ID: 24955866 [TBL] [Abstract][Full Text] [Related]
39. Novel Approaches to Optimization of Levodopa Therapy for Parkinson's Disease. Kianirad Y; Simuni T Curr Neurol Neurosci Rep; 2016 Apr; 16(4):34. PubMed ID: 26898686 [TBL] [Abstract][Full Text] [Related]
40. Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease. Yokochi M Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S25-30. PubMed ID: 19131038 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]